 Connection
Jens Kuhn to Cell Line, Tumor
This is a "connection" page, showing publications Jens Kuhn has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.156 |
|
|
|
-
Bennett RP, Postnikova EN, Eaton BP, Cai Y, Yu S, Smith CO, Liang J, Zhou H, Kocher GA, Murphy MJ, Smith HC, Kuhn JH. Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties. JCI Insight. 2022 01 11; 7(1).
Score: 0.101
-
Cai Y, Yu S, Chi X, Radoshitzky SR, Kuhn JH, Berger EA. An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells. PLoS One. 2021; 16(1):e0245024.
Score: 0.023
-
Pleet ML, Erickson J, DeMarino C, Barclay RA, Cowen M, Lepene B, Liang J, Kuhn JH, Prugar L, Stonier SW, Dye JM, Zhou W, Liotta LA, Aman MJ, Kashanchi F. Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles. J Infect Dis. 2018 11 22; 218(suppl_5):S365-S387.
Score: 0.020
-
Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011 Jan 06; 7(1):e1001258.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|